Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Anemia is a prevalent complication in chronic kidney disease, linked to increased comorbidity and mortality. Erythropoietin deficiency is a key contributor, and erythropoiesis-stimulating agents (ESAs) are a cornerstone of anemia management. Systemic inflammation, reflected by the Neutrophil-to-Lymphocyte Ratio (NLR), is a known driver of erythropoietin resistance in hemodialysis patients. This study investigates the association between NLR and Erythropoietin Resistance Index (ERI) in maintenance hemodialysis patients
A total of 54 patients above 18 years of age on regular hemodialysis for at least 3 months were included. NLR and erythropoietin resistance (ERI) was calculated and association were analyzed using chi-square and correlation tests with a significance level of p <0.05. Inflammatory and Iron studies variables were compared among groups. Receiver operating characteristic (ROC) curve analysis was done to evaluate how well the NLR predicts erythropoietin resistance, defined as an ERI score greater than 10.
A mean age was 64.04 ± 13.22 years. The majority were female (53.7%), hypertensive (81.48%), and diabetic (50%). Laboratory findings revealed a high prevalence of anemia (61.1% with low hemoglobin) and inflammation (63% with elevated NLR). ROC curve analysis identified an optimal NLR cut-off of >3.67 for predicting erythropoietin resistance (ERI >10), yielding an AUC of 0.68 (p = 0.016), sensitivity of 75.86%, and specificity of 60%. Subgroup analysis among patients with normal ferritin but low TSAT demonstrated a higher discriminatory performance (AUC 0.74, p = 0.027). Comparison with prior studies showed similar predictive accuracy.
Elevated NLR levels are significantly associated with increased erythropoietin resistance in hemodialysis patients, suggesting its utility as a cost-effective and accessible biomarker. With an NLR cut-off of >3.67 moderately predicting high erythropoietin resistance, integrating NLR into routine anemia management can help identify hyporesponsive patients early, enabling timely optimization of erythropoietin therapy and potentially improving patient outcomes. Further prospective research is warranted to confirm these findings.
